Literature DB >> 330067

Immunobiology of primary intracranial tumours. II. Analysis of lymphocyte subpopulations in patients with primary brain tumours.

W H Brooks, T L Roszman, M S Mahaley, R E Woosley.   

Abstract

Circulating peripheral blood lymphocyte subpopulations were analysed in patients with primary intracranial neoplasia. Patients with tumours of glial origin demonstrated a significant depletion of E-rosetting lymphocytes whereas the quantitative lymphocyte profiles of patients with non-glial brain tumours were normal. The number of immunoglobulin and Fe receptor-bearing cells was not significantly altered in any group of patients: however, the EAC-RFC subpopulation was increased in those with malignant gliomas. Two hypotheses are suggested to explain these observations: first, the presence of cross-reacting antibody between T cells and brain (glial) cells, and secondly, the proliferation of EAC-RFC in response to malignant degeneration.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330067      PMCID: PMC1541043     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Demonstration of a complement of inactivator on cultured cells from human malignant brain tumours.

Authors:  K Osther; K Hojgaard; E Dybkjaer
Journal:  Acta Neurol Scand       Date:  1974       Impact factor: 3.209

2.  Immune responses in patients with gliomas.

Authors:  W H Brooks; H D Caldwell; R H Mortara
Journal:  Surg Neurol       Date:  1974-11

3.  Brain-associated theta antigen: reactivity of rabbit anti-mouse brain with mouse lymphoid cells.

Authors:  E S Golub
Journal:  Cell Immunol       Date:  1971-08       Impact factor: 4.868

4.  Studies on the human T-lymphocyte population. II. The use of a T-cell specific antibody in the partial isolation and characterization of the human lymphocyte receptor for sheep red blood cells.

Authors:  F L Owen; M W Fanger
Journal:  J Immunol       Date:  1974-10       Impact factor: 5.422

5.  Is the brain an "immunologically privileged site"? 2. Studies in induced host resistance to transplantable mouse glioma following irradiation of prior implants.

Authors:  L C Scheinberg; A Levy; F Edelman
Journal:  Arch Neurol       Date:  1965-09

Review 6.  Biological inhibitors of lymphoid cell division.

Authors:  D F Ranney
Journal:  Adv Pharmacol Chemother       Date:  1975

7.  E and EAC rosetting lymphocytes in patients with carcinoma of bronchus. II. A sequential study of thirty patients: effect of BCG.

Authors:  H M Anthony; J A Kirk; K E Madsen; M K Mason; G H Templeman
Journal:  Clin Exp Immunol       Date:  1975-04       Impact factor: 4.330

8.  Specificity of human lymphocyte complement receptors.

Authors:  G D Ross; M J Polley
Journal:  J Exp Med       Date:  1975-05-01       Impact factor: 14.307

9.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

10.  Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor.

Authors:  W H Brooks; M G Netsky; D E Normansell; D A Horwitz
Journal:  J Exp Med       Date:  1972-12-01       Impact factor: 14.307

View more
  30 in total

Review 1.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  African wild dogs test the 'survival of the fittest' paradigm.

Authors:  Alistair Pole; Iain J Gordon; Martyn L Gorman
Journal:  Proc Biol Sci       Date:  2003-08-07       Impact factor: 5.349

3.  Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone.

Authors:  Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

Review 4.  Genetic and molecular epidemiology of adult diffuse glioma.

Authors:  Annette M Molinaro; Jennie W Taylor; John K Wiencke; Margaret R Wrensch
Journal:  Nat Rev Neurol       Date:  2019-06-21       Impact factor: 42.937

Review 5.  Embracing rejection: Immunologic trends in brain metastasis.

Authors:  S Harrison Farber; Vadim Tsvankin; Jessica L Narloch; Grace J Kim; April K S Salama; Gordana Vlahovic; Kimberly L Blackwell; John P Kirkpatrick; Peter E Fecci
Journal:  Oncoimmunology       Date:  2016-04-11       Impact factor: 8.110

Review 6.  The immunobiology of human gliomas.

Authors:  V Piguet; A C Diserens; S Carrel; J P Mach; N de Tribolet
Journal:  Springer Semin Immunopathol       Date:  1985

Review 7.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

8.  T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.

Authors:  Karolina Woroniecka; Pakawat Chongsathidkiet; Kristen Rhodin; Hanna Kemeny; Cosette Dechant; S Harrison Farber; Aladine A Elsamadicy; Xiuyu Cui; Shohei Koyama; Christina Jackson; Landon J Hansen; Tanner M Johanns; Luis Sanchez-Perez; Vidyalakshmi Chandramohan; Yen-Rei Andrea Yu; Darell D Bigner; Amber Giles; Patrick Healy; Glenn Dranoff; Kent J Weinhold; Gavin P Dunn; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-02-07       Impact factor: 12.531

9.  Inability of mitogen-activated lymphocytes obtained from patients with malignant primary intracranial tumors to express high affinity interleukin 2 receptors.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

10.  Depressed T lymphocyte function in brain tumor patients: monocytes as suppressor cells.

Authors:  G W Wood; R A Morantz
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.